Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.

ABSTRACT:

Background

Concomitant drug administration is a general phenomenon in patients with chronic diseases such as diabetes mellitus. Among the currently available oral antidiabetic drugs, gliclazide is a commonly prescribed drug considering its multiple benefits in diabetic patients. Aprepitant is a commonly prescribed antiemetic drug which is mainly metabolized by CYP3A4, reported to have modest inductive and inhibitory effects on CYP2C9 and CYP3A4, respectively. Since gliclazide is metabolized by CYP2C9 (major) and CYP3A4 (minor), it is very difficult to predict the influence of aprepitant and its metabolic interaction with gliclazide. Considering the complexity associated with the combination of aprepitant and gliclazide, this study was designed to evaluate the influence of aprepitan

SUBMITTER: Kura RR 

PROVIDER: S-EPMC5969050 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature